Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Wednesday, Nov. 27, 2013, 160 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $788.24 to $484,583,953.98.

Highlighted Stocks Traded by Insiders:

Aspen Insurance Holdings (AHL) - FREE Research Report

Boornazian Brian who is Chairman Aspen Re at Aspen Insurance Holdings sold 20,000 shares at $40.58 on Nov. 27, 2013. Following this transaction, the Chairman Aspen Re owned 95,108 shares meaning that the stake was reduced by 17.37% with the 20,000 share transaction.

The shares most recently traded at $40.72, up $0.14, or 0.33% since the insider transaction. Historical insider transactions for Aspen Insurance Holdings go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares sold: 50,667
  • 24-Week # shares bought: 5,300
  • 24-Week # shares sold: 90,599

The average volume for Aspen Insurance Holdings has been 445,700 shares per day over the past 30 days. Aspen Insurance Holdings has a market cap of $2.7 billion and is part of the financial sector and insurance industry. Shares are up 26.37% year to date as of the close of trading on Wednesday.

Aspen Insurance Holdings Limited, through its subsidiaries, provides insurance and reinsurance solutions worldwide. It operates in two segments, Reinsurance and Insurance. The stock currently has a dividend yield of 1.78%. The company has a P/E ratio of 14.2. Currently there is 1 analyst that rates Aspen Insurance Holdings a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AHL - FREE

TheStreet Quant Ratings

rates Aspen Insurance Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Aspen Insurance Holdings Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Concur Technologies (CNQR) - FREE Research Report

Torrey John T. who is EVP Corporate Strategy at Concur Technologies sold 1,175 shares at $97.61 on Nov. 27, 2013. Following this transaction, the EVP Corporate Strategy owned 7,720 shares meaning that the stake was reduced by 13.21% with the 1,175 share transaction.

The shares most recently traded at $97.19, down $0.42, or 0.43% since the insider transaction. Historical insider transactions for Concur Technologies go as follows:

  • 4-Week # shares sold: 14,175
  • 12-Week # shares sold: 25,175
  • 24-Week # shares sold: 123,629

The average volume for Concur Technologies has been 539,700 shares per day over the past 30 days. Concur Technologies has a market cap of $5.4 billion and is part of the technology sector and computer software & services industry. Shares are up 42.8% year to date as of the close of trading on Wednesday.

Concur Technologies, Inc. provides integrated travel and expense management solutions for companies worldwide. Currently there are 5 analysts that rate Concur Technologies a buy, 2 analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CNQR - FREE

TheStreet Quant Ratings

rates Concur Technologies as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full

Concur Technologies Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Chemed Corporation (CHE) - FREE Research Report

Williams David Patrick who is executive vice president & CFO at Chemed Corporation sold 5,000 shares at $78.91 on Nov. 27, 2013. Following this transaction, the executive vice president & CFO owned 41,180 shares meaning that the stake was reduced by 10.83% with the 5,000 share transaction.

The shares most recently traded at $77.92, down $0.99, or 1.27% since the insider transaction. Historical insider transactions for Chemed Corporation go as follows:

  • 4-Week # shares sold: 22,186
  • 12-Week # shares sold: 22,186
  • 24-Week # shares sold: 40,586

The average volume for Chemed Corporation has been 267,300 shares per day over the past 30 days. Chemed Corporation has a market cap of $1.4 billion and is part of the health care sector and health services industry. Shares are up 13.27% year to date as of the close of trading on Wednesday.

Chemed Corporation, through its subsidiaries, operates in the healthcare, and repair and maintenance fields in the United States. The company operates in two segments, Vitas and Roto-Rooter. The stock currently has a dividend yield of 1.03%. The company has a P/E ratio of 18.1. Currently there is 1 analyst that rates Chemed Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CHE - FREE

TheStreet Quant Ratings

rates Chemed Corporation as a

buy

. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations, increase in stock price during the past year and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Chemed Corporation Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Isis Pharmaceuticals (ISIS) - FREE Research Report

Wender Joseph H who is Director at Isis Pharmaceuticals sold 10,000 shares at $36.63 on Nov. 27, 2013. Following this transaction, the Director owned 45,866 shares meaning that the stake was reduced by 17.9% with the 10,000 share transaction.

Klein Joseph Iii who is Director at Isis Pharmaceuticals sold 6,000 shares at $36.86 on Nov. 27, 2013. Following this transaction, the Director owned 2,313 shares meaning that the stake was reduced by 72.18% with the 6,000 share transaction.

The shares most recently traded at $39.64, up $2.78, or 7.01% since the insider transaction. Historical insider transactions for Isis Pharmaceuticals go as follows:

  • 4-Week # shares sold: 16,000
  • 12-Week # shares sold: 17,985
  • 24-Week # shares sold: 23,011

The average volume for Isis Pharmaceuticals has been 1.5 million shares per day over the past 30 days. Isis Pharmaceuticals has a market cap of $4.6 billion and is part of the health care sector and drugs industry. Shares are up 276.25% year to date as of the close of trading on Wednesday.

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. Currently there are 3 analysts that rate Isis Pharmaceuticals a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ISIS - FREE

TheStreet Quant Ratings

rates Isis Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full

Isis Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Monster Beverage (MNST) - FREE Research Report

Schlosberg Hilton H who is Vice Chairman and President at Monster Beverage sold 35,000 shares at $59.21 on Nov. 27, 2013. Following this transaction, the Vice Chairman and President owned 1.4 million shares meaning that the stake was reduced by 2.41% with the 35,000 share transaction.

Sacks Rodney C who is Chairman and CEO at Monster Beverage sold 35,000 shares at $59.24 on Nov. 27, 2013. Following this transaction, the Chairman and CEO owned 1.5 million shares meaning that the stake was reduced by 2.25% with the 35,000 share transaction.

The shares most recently traded at $59.37, up $0.13, or 0.22% since the insider transaction. Historical insider transactions for Monster Beverage go as follows:

  • 4-Week # shares sold: 72,700
  • 12-Week # shares bought: 57
  • 12-Week # shares sold: 142,700
  • 24-Week # shares bought: 57
  • 24-Week # shares sold: 144,290

The average volume for Monster Beverage has been 1.6 million shares per day over the past 30 days. Monster Beverage has a market cap of $10.0 billion and is part of the consumer goods sector and food & beverage industry. Shares are up 13.27% year to date as of the close of trading on Wednesday.

Monster Beverage Corporation, through its subsidiaries, develops, markets, sells, and distributes alternative beverage category beverages in the United States and internationally. The company has a P/E ratio of 31.5. Currently there are 4 analysts that rate Monster Beverage a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNST - FREE

TheStreet Quant Ratings

rates Monster Beverage as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full

Monster Beverage Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by

Zacks Investment Research

null